Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Study results from Tel-Aviv University in the area of immunization published
July 30th, 2008
In this recently published article, scientists in Tel Aviv, Israel conducted a study "To assess the effect of rituximab on the efficacy and safety of influenza virus vaccine in patients with rheumatoid arthritis (RA). The study group comprised patients with RA treated with conventional disease-modifying drugs with or without rituximab." "Split-virion inactivated vaccine containing 15 mu g haemagglutinin/dose of B/Shanghai/361/02 (SHAN), A/New Caledonian/20/99 (NC) (H1N1) and A/California/7/04 (CAL) (H3N2) was used. Disease activity was assessed by the number of tender and swollen joints, duration of morning stiffness and evaluation of pain on the day of vaccination and...
Source: Vaccine Weekly (2008-07-30)
|
